BOSTON SCIENTIFIC CORP(BSX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #49 of 2,879 stocksTOP 5%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BSX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BOSTON SCIENTIFIC CORP (BSX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BSX at 79.9/100 on a 32-signal composite quality model, placing it at rank #49 of 2,879 stocks — the top 5% of the AI-ranked universe. BSX scores in the top quartile across revenue scale (92.8), profitability (85.9), earnings quality (84.7). Shareholder dilution risk is elevated at 47.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BOSTON SCIENTIFIC CORP reports quarterly revenue of $5.2B, net income of $1.3B, an operating margin of 21.2%. Top institutional holders of BSX by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. BSX trades on the NYSE exchange and files with the SEC under CIK 885725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BOSTON SCIENTIFIC CORP directly from SEC EDGAR. BOSTON SCIENTIFIC CORP's 13F Pro composite quality score has ranged between 8 and 80 since 2021, currently 79.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving BSX's Business? Latest 10-Q Breakdown
✓ 14/14 datapoints verifiedAI-extracted from BOSTON SCIENTIFIC CORP's 10-Q filed 2026-05-01 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Boston Scientific grew Q1 revenue 11.6% to $5.2B, driven by Electrophysiology and Cardiovascular strength, while discrete tax benefit of $384M lifted net income 98.8% to $1.3B.
Biggest Revenue Drivers
Total revenue: $5.203B+11.6% YoY
Driven by Electrophysiology (Farapulse PFA System, WATCHMAN devices) and Interventional Cardiology (AGENT Drug-Coated Balloon coronary therapies).
Led by Endoscopy biliary and endoluminal surgery franchises; Urology and Neuromodulation growth included comprehensive pain portfolio and Intracept System.
Largest Expense Items
Increase driven by selling expenses associated with higher net sales and product launches.
Investments across businesses to maintain pipeline of products for future sales growth.
Higher sales volume and favorable product mix improved gross margin to 69.4% from 68.8% prior year.
Margins: Gross margin expanded 60 basis points to 69.4%, driven by higher-margin product sales and lower inventory step-up charges from acquisitions, partially offset by unfavorable foreign currency impacts. Operating margin improved as operating income grew faster than net sales.
Watch Items from the Filing
- Penumbra acquisition ($14.5B announced January 2026) received FTC Second Request in March 2026; deal completion expected H2 2026 with $6B term loan facility secured but regulatory approval uncertain.
- Urology business faced headwinds from China volume-based procurement and sacral neuromodulation commercial disruption; Electrophysiology experiencing increased competition.
- Contingent consideration liability of $354M as of Q1 2026 (down from $385M year-end 2025), with maximum uncapped payments of $132M and capped arrangements of ~$671M total.
- Multiple product liability and patent litigation matters pending; transvaginal mesh settlement framework established; new SCS devices MDL filed February 2026 with hearing scheduled May 2026.
- Foreign currency headwind of 2.2% YoY on reported sales; net currency translation loss of $11M in Q1 2026 from derivative and transaction exposures.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$5.2B
Net Income
Q1 2026
$1.3B
Free Cash Flow
Q1 2026
$171.0M
Operating Margin
Q1 2026
21.2%
D/E Ratio
Q1 2026
0.43
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+68.9% YoYOperating Income
+201.3% YoYEPS (Diluted)
+181.2% YoYTotal Assets
+35.5% YoYTotal Debt
+26.2% YoYOp. Cash Flow
+142.5% YoY| Metric | FY 2025 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $20.07B +68.9% | $11.89B +19.9% | $9.91B -7.7% | $10.73B +9.3% | $9.82B +8.6% | $9.05B |
| Operating Income | $3.61B +201.3% | $1.20B +1598.8% | $-80.0M -105.3% | $1.52B +0.8% | $1.51B +17.2% | $1.28B |
| EPS (Diluted) | $1.94 +181.2% | $0.69 +962.5% | $-0.08 -102.4% | $3.33 +179.8% | $1.19 +1387.5% | $0.08 |
| Total Assets | $43.67B +35.5% | $32.23B +4.7% | $30.78B +0.7% | $30.57B +45.6% | $21.00B +10.3% | $19.04B |
| Total Debt | $11.44B +26.2% | $9.06B -0.9% | $9.14B -8.6% | $10.01B +41.8% | $7.06B +25.6% | $5.62B |
| Operating Cash Flow | $4.53B +142.5% | $1.87B +24.0% | $1.51B -17.9% | $1.84B +492.3% | $310.0M -78.3% | $1.43B |
AI Insight: BSX Financial Trends
Boston Scientific delivered strong revenue growth from $4.1B to $5.2B over eight quarters, but operating cash flow turned volatile with Q1 2026 dropping to just $348M.
• Revenue grew 26% from $4,121M in Q2 2024 to $5,203M in Q1 2026.
• Operating income surged 112% from $520M in Q2 2024 to $1,101M in Q1 2026.
• Equity strengthened from $20,371M in Q2 2024 to $25,864M in Q1 2026.
⚠ Operating cash flow plunged 74% from $1,364M in Q4 2025 to $348M in Q1 2026.
⚠ Total debt increased from $10,571M in Q2 2024 to $11,029M in Q1 2026.
AI Insight: BSX Ratio Trends
Operating margin surged to 21.2% in Q1 2026, the highest level in the dataset, while debt-to-equity improved to 0.43.
• Operating margin expanded from 12.6% in Q2 2024 to 21.2% in Q1 2026, showing strong operational efficiency gains.
• ROIC improved from 6.7% in Q2 2024 to 11.9% in Q1 2026, indicating better capital allocation.
• Debt-to-equity ratio decreased from 0.53 in Q3 2024 to 0.43 in Q1 2026, strengthening balance sheet.
⚠ Operating margin shows quarter-to-quarter volatility, dropping from 20.7% in Q3 2025 to 15.6% in Q4 2025.
⚠ ROIC declined from 12.0% in Q3 2025 to 9.2% in Q4 2025 before recovering in Q1 2026.
Get alerted when BSX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BOSTON SCIENTIFIC CORP including:
Top Institutional Holders of BSX
BlackRock, Inc.
$8.3B131,822,037 shVANGUARD CAPITAL MANAGEMENT LLC
$6.0B96,411,568 shFMR LLC
$4.7B74,226,395 shSTATE STREET CORP
$4.3B67,986,847 shGEODE CAPITAL MANAGEMENT, LLC
$2.1B33,285,757 shPRIMECAP MANAGEMENT CO/CA/
$2.0B32,529,774 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.9B29,796,211 shD. E. Shaw & Co., Inc.
$1.5B24,312,352 shBANK OF AMERICA CORP /DE/
$1.4B22,756,646 shMORGAN STANLEY
$1.4B22,266,664 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $8.3B | 131,822,037 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.0B | 96,411,568 |
| FMR LLC | $4.7B | 74,226,395 |
| STATE STREET CORP | $4.3B | 67,986,847 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.1B | 33,285,757 |
| PRIMECAP MANAGEMENT CO/CA/ | $2.0B | 32,529,774 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.9B | 29,796,211 |
| D. E. Shaw & Co., Inc. | $1.5B | 24,312,352 |
| BANK OF AMERICA CORP /DE/ | $1.4B | 22,756,646 |
| MORGAN STANLEY | $1.4B | 22,266,664 |
More Healthcare Companies
View all Healthcare →Put BSX on your watchlist
Track score changes the day BOSTON SCIENTIFIC CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BSX a good stock to buy?
13F Pro's AI-powered analysis of BOSTON SCIENTIFIC CORP (BSX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BSX are available on the BSX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BSX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BSX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BOSTON SCIENTIFIC CORP's investment landscape.